The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Former Bachelorette star Katie Thurston is sharing a major update on her cancer journey after having to put her treatments on ...

The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Quantitative assessment of psoriatic epidermal hyperplasia in human skin grafts after oligonucleotide ... A.B. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis.

The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a ...

Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 11.17%, which has investors questioning if this is right time to buy.

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 31.15%, which has investors questioning if this is right time ...